Welcome to our dedicated page for Zimmer Biomet Holdings news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet Holdings stock.
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) is a preeminent global leader in musculoskeletal healthcare. Headquartered in Warsaw, Indiana, Zimmer Biomet has been at the forefront of advancing bone and joint health for nearly 90 years. The company designs, manufactures, and markets a comprehensive range of orthopedic implants and surgical equipment, addressing joint reconstruction, bone repair, sports medicine, spine, and dental reconstruction. Its innovative product portfolio includes the ROSA® Robotics systems for knee, hip, and shoulder replacements, and the TMINI Miniature Robotic System for total knee arthroplasty.
Zimmer Biomet's latest endeavors include the establishment of a dedicated Health Equity division in 2023, which aims to integrate health equity into the company's core strategies and operations. This division has already made significant strides by assembling a strategic advisory board and developing the Community Centered Care (C3) framework to increase patient access to quality care in underserved communities.
In addition, Zimmer Biomet has recently partnered with top pickleball organizations in the U.S., underscoring its commitment to joint health and well-being for the growing community of pickleball players. The company also announced a strategic alliance with CBRE Group, Inc. to expand orthopedic ambulatory surgery centers across the country, and a collaboration with RevelAi Health to commercialize AI-powered engagement solutions aimed at advancing value-based orthopedic care and health equity.
Financially, Zimmer Biomet has demonstrated robust performance, with first-quarter 2024 net sales amounting to $1.889 billion, a 3.2% year-over-year increase. The company continues to focus on innovation, operational excellence, and strategic partnerships to drive growth and enhance shareholder value. For more information, visit www.zimmerbiomet.com or follow them on LinkedIn and Twitter.
Zimmer Biomet (NYSE: ZBH) has received CE Mark certification for its Persona® Revision Knee System, expanding its availability in European markets. The system, which leads the $700+ million U.S. knee revision market, offers personalized solutions for revision knee arthroplasty. It features Trabecular Metal™ Technology for improved implant fixation and bone in-growth, along with modular components that enable surgeons to address complex cases with greater precision. The system's anatomic components and instrumentation are designed to streamline revision surgery while allowing intraoperative adjustments for optimal alignment and fit.
Zimmer Biomet (NYSE: ZBH) has announced a partnership with Arnold Schwarzenegger as their new Chief Movement Officer. In this strategic role, Schwarzenegger will work to motivate and support individuals in increasing mobility, maintaining joint health, and incorporating movement into daily routines. The partnership aligns with Zimmer Biomet's mission as a MedTech leader to alleviate pain and improve quality of life worldwide. Schwarzenegger, known for his 50-year fitness advocacy through various platforms including the Arnold Sports Festival and 'Arnold's Pump Club' newsletter, will collaborate with the company to promote active living and wellness initiatives.
Zimmer Biomet (NYSE and SIX: ZBH) has announced its participation in the upcoming Jefferies London Healthcare Conference. The company's management team will engage in a fireside chat on November 19, 2024, at 11:00 a.m. GMT (6:00 a.m. ET). Investors and interested parties can access a live webcast of the presentation through Zimmer Biomet's Investor Relations website. The presentation will be available for replay after the conference.
Zimmer Biomet (NYSE: ZBH) reported Q3 2024 financial results with net sales of $1.824 billion, representing a 4.0% increase year-over-year. The company achieved net earnings of $249.1 million, with diluted EPS of $1.23 and adjusted diluted EPS of $1.74. Notable developments include the planned launch of the Z1™ Femoral Hip System and acquisition of OrthoGrid Systems. However, due to ERP implementation challenges, the company has updated its 2024 guidance, reducing full-year revenue growth expectations to 3.5-4.0% from previous 4.0-5.0%, and narrowing adjusted EPS guidance to $7.95-$8.05 from $8.00-$8.15.
Zimmer Biomet announced the commercial launch of its new Z1™ Femoral Hip System at the 2024 AAHKS Annual Meeting. The Z1 System, featuring a triple-taper design, integrates with the company's G7® Acetabular System to provide a comprehensive hip arthroplasty solution. The system offers collared and collarless options, three distinct neck options, and uses a single streamlined instrument tray. The company also highlighted its recent acquisition of OrthoGrid Systems, adding AI-powered surgical assistance applications to its portfolio. Clinical data on the G7 Acetabular System's safety and durability will be presented at the meeting.
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) has announced its upcoming third quarter 2024 earnings conference call. The event will be webcast on Wednesday, October 30, 2024, at 8:30 a.m. ET. A news release containing the quarterly results will be made available earlier that day at 6:30 a.m. ET.
Investors and interested parties can access the live audio webcast through Zimmer Biomet's Investor Relations website. For those who prefer to dial in, U.S. and Canadian participants can call (888) 204-4368, while international callers should use +1 (323) 994-2093. Both should use the conference ID 5103691. The webcast will be available for replay following the conference call.
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) has announced the appointment of David DeMartino as Senior Vice President, Investor Relations, effective September 9, 2024. Reporting to CEO Ivan Tornos, DeMartino will lead the company's investor relations strategy and manage relationships with the investment community. With over 25 years of experience in healthcare, including asset management and equity research, DeMartino brings valuable industry knowledge to the role.
Prior to joining Zimmer Biomet, DeMartino served as Chief Strategy Officer at Nyxoah and held positions at DNB Asset Management, Velan Capital, Citadel, and Pura Vida Investments. His background also includes sell-side equity research at Deutsche Bank and Credit Suisse, as well as investment banking experience.
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, has announced a quarterly cash dividend for the third quarter of 2024. The company's Board of Directors has approved a dividend of $0.24 per share, which will be payable on or about October 31, 2024 to stockholders of record as of the close of business on September 30, 2024. This announcement demonstrates Zimmer Biomet's commitment to providing regular returns to its shareholders and reflects the company's financial stability.
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, has announced its participation in two major healthcare conferences in September 2024. The company's management team will present at the Wells Fargo 2024 Healthcare Conference on September 5 at 8:00 a.m. ET, followed by a presentation at the Morgan Stanley Annual Global Healthcare Conference on September 6 at 9:15 a.m. ET.
Investors and interested parties can access live webcasts of both presentations through Zimmer Biomet's Investor Relations website. These webcasts will also be archived for later viewing. This participation in high-profile healthcare conferences demonstrates Zimmer Biomet's commitment to engaging with the investment community and sharing insights about their business and industry trends.
Zimmer Biomet (NYSE: ZBH) reported strong Q2 2024 financial results, with net sales of $1.942 billion, up 3.9% year-over-year and 5.6% on a constant currency basis. Diluted earnings per share were $1.18, while adjusted diluted EPS reached $2.01. The company's performance was driven by customer demand for its diversified products and strong international business. Zimmer Biomet updated its 2024 reported revenue guidance due to currency expectations but reaffirmed constant currency revenue growth and adjusted EPS guidance. Notable highlights include the acquisition of OrthoGrid Systems, a partnership with THINK Surgical for robotic systems, and a co-marketing agreement with RevelAi Health for AI-powered technology.
FAQ
What is the current stock price of Zimmer Biomet Holdings (ZBH)?
What is the market cap of Zimmer Biomet Holdings (ZBH)?
What does Zimmer Biomet do?
Where is Zimmer Biomet headquartered?
What are Zimmer Biomet's latest innovations?
What is Zimmer Biomet's focus on health equity?
How did Zimmer Biomet perform financially in the first quarter of 2024?
What are Zimmer Biomet's partnerships?
What is the ROSA® Robotics system?
What is the Community Centered Care (C3) framework?
What is Zimmer Biomet's role in pickleball?
How does Zimmer Biomet contribute to innovation in healthcare?
